Custom Antibody Services Market Report By Insights, Size, and Growth - 2031

The market for custom antibody services is anticipated to expand significantly, with projections indicating growth from approximately US$ 590.33 million in 2023 to around US$ 1,216.35 million by 2031. This growth trajectory suggests a compound annual growth rate (CAGR) of 9.5% from 2023 to 2031. Key drivers of this market expansion include the rising incidence of chronic diseases and an increase in the approval rates of biosimilars. Nevertheless, the high expenses and intricate processes involved in producing antibodies through transgenic animals pose challenges to the growth of the custom antibody services sector.

Recombinant antibody engineering presents vast opportunities for researchers and drug developers to design specific molecules tailored for the treatment of particular diseases. Many pharmaceutical companies are now leveraging artificial intelligence (AI) technologies to predict and analyze potential therapeutics derived from antibody sequences. These algorithms evaluate the viability of these therapeutics prior to their actual production. For example, Foundation Medicine specializes in developing, manufacturing, and marketing genomic profiling assays based on next-generation sequencing technology, which are applicable to solid tumors, hematologic malignancies, and sarcomas. These assays assist in aligning patients with targeted therapies, immunotherapies, and clinical trial opportunities. Additionally, such organizations collaborate with the biopharmaceutical sector to facilitate the discovery, development, and distribution of innovative treatments for patients. The Medicines Discovery Catapult is currently exploring an in-silico pipeline to identify new molecules for cancer therapies, utilizing AI to uncover new disease drivers and potential drug candidates for lung cancer. Therefore, advancements in technology related to recombinant antibodies are likely to introduce new trends in the custom antibody services market in the near future.

Insights Based on Application

The custom antibody services market is categorized by application into several segments, including immunohistochemistry, western blotting and immunoprecipitation (IP), enzyme-linked immunosorbent assay (ELISA), fluorescence-activated cell sorting, mass spectrometry, and others. Among these, the ELISA segment accounted for the largest share of the custom antibody services market in 2023. The enzyme-linked immunosorbent assay (ELISA) is a diagnostic test that identifies and quantifies antibodies present in an individual's blood. This test can determine the presence of antibodies associated with various infectious diseases, including bacterial, viral, and fungal infections. ELISA serves as an immunological assay that quantifies antibodies, antigens, proteins, and glycoproteins in biological samples. Common applications include diagnosing HIV infections, conducting pregnancy tests, and measuring cytokines or soluble receptors in serum or cell supernatants. Monoclonal antibodies, which are produced by a single clone of B-cells and target a specific epitope on an antigen, are utilized in medical diagnostics, including ELISA tests, which are known for their speed and reliability. Beyond providing qualitative results regarding the presence or absence of an analyte in a sample, ELISAs can also deliver quantitative measurements of protein or peptide levels across numerous samples, offering a significant advantage over related techniques such as immunohistochemistry (IHC), immunocytochemistry (ICC), or western blotting.

The custom antibody services market report is informed by various primary and secondary sources, including the Centers for Disease Control and Prevention, the International Diabetes Federation, and the American Cancer Society.